Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05857514
Other study ID # ECR/922/inst/UP/RR-2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 10, 2023
Est. completion date May 1, 2024

Study information

Verified date June 2023
Source Moti Lal Nehru Medical College
Contact Mukti Pr Meher, MBBS, MD
Phone 9556694521
Email drmuktiprakash@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis. The main question it aims to answer is: whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis Participants will be patients who give consent to the study and who are required to undergo ERCP as part of their standard care. If there is a comparison group: Researchers will compare [rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis.] to see if [whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis].


Recruitment information / eligibility

Status Recruiting
Enrollment 384
Est. completion date May 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Suspected sphincter of Oddi dysfunction 2. History of post ERCP Pancreatitis 3. Pancreatic instrumentation or sphincterotomy. 4. Precut sphincteroyomy 5. Difficult cannulation defined by more than 5 cannulation attempts 6. The use of double wire technique in bile duct access 7. At least 2 of the followings including 1. Female age < 50 year 2. 3 pancreatogram 3. Acinarization (Contrast injection to tail of pancreas 4. Normal serum bilirubin 5. Guidewire to the tail of pancreas or secondary branches Exclusion Criteria: 1. Patient planned for pancreatic stenting 2. Without informed consent 3. Age < 18 years 4. Pregnant women 5. Lactating women 6. Patient with altered anatomy 7. Contraindications to the use of NSAIDS 8. Renal failure 9. Ongoing or recent hospitalisation for acute pancreatitis 10. Allergy to aspirin or NSAIDs 11. known chronic calcific pancreatitis -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rectal Indomethacin
Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis
Procedure:
Prophylactic Pancreatic duct stenting
Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis

Locations

Country Name City State
India Department of Gastroenterology and Hepatology Allahabad Uttar Pradesh
India Department of Gastroenterology and Hepatology, MLN Medical college and SRN Hospital Allahabad Uttar Pradesh

Sponsors (1)

Lead Sponsor Collaborator
Moti Lal Nehru Medical College

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary To compare rectal indomethacin alone versus combined pancreatic duct stent and rectal indomethacin in prevention of post ERCP pancreatitis For comparison between these two arms the investigators will measure serum amylase in U/L value after 6 hour and 24 hour of the ERCP procedure. The investigators will also assess for pain abdomen and vomiting suggestive of acute pancreatitis. 24 hour
See also
  Status Clinical Trial Phase
Completed NCT04546867 - Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal N/A
Terminated NCT02241512 - IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis Phase 2
Completed NCT00222092 - Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers Phase 4
Completed NCT05310409 - PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
Not yet recruiting NCT06260878 - Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis Phase 4
Not yet recruiting NCT04770857 - Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
Completed NCT02641561 - Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis Phase 3
Active, not recruiting NCT04145336 - 7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients N/A
Completed NCT03629600 - Trial of Aggressive Hydration Versus Rectal Indomethacin for Prevention of Post-ERCP Pancreatitis Phase 2/Phase 3
Recruiting NCT03756116 - Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide N/A
Recruiting NCT05664074 - Rectal Indomethacin vs Intravenous Ketorolac Phase 4
Completed NCT02308891 - A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis N/A
Recruiting NCT05336630 - Study of Forceps Cannulation During ERCP N/A
Recruiting NCT05267379 - An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis
Recruiting NCT05947461 - Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac N/A
Completed NCT03098082 - Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis N/A
Recruiting NCT02839356 - Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis Phase 4
Recruiting NCT02830984 - ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP N/A
Completed NCT01673763 - Post-ERCP Pancreatitis Prevention by Stent Insertion N/A
Active, not recruiting NCT04425993 - Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP Prevention N/A